The global landscape of tuberculosis (TB) diagnostics is undergoing a significant transformation following new recommendations issued by the World Health Organization (WHO), aimed at substantially improving access to faster, more efficient testing. These groundbreaking guidelines, detailed in a recent WHO news release, introduce near point-of-care molecular testing, alternative sample collection methods such as tongue swabs, and pooled testing strategies. This global push for decentralized and cost-effective diagnostics stands in notable contrast to the Centers for Disease Control and Prevention’s (CDC) more targeted, risk-based approach to TB control within the United States, highlighting the diverse epidemiological realities and resource capacities that shape public health strategies worldwide.
WHO’s Groundbreaking Recommendations: A Paradigm Shift in Global TB Diagnostics
At the heart of WHO’s updated guidance, which will be formally incorporated into Module 3: Diagnosis guidelines later this year, is a strategic pivot towards decentralization and scalability in TB diagnostics. For the first time, WHO is endorsing a new class of near point-of-care nucleic acid amplification tests (NPOC-NAATs). These innovative systems are designed for deployment in peripheral healthcare settings, including primary care clinics and community health centers, far removed from centralized laboratories. This shift is poised to deliver faster results at a significantly lower cost compared to traditional, often complex, laboratory-based molecular platforms, effectively bringing TB testing closer to the patient and dramatically reducing diagnostic turnaround times.
The rationale behind embracing NPOC-NAATs is deeply rooted in addressing the persistent diagnostic gaps that plague many high-burden and resource-limited settings globally. Conventional TB diagnostic pathways often involve multiple steps: patients may need to travel long distances to health facilities, provide sputum samples, and then wait days or even weeks for results from centralized laboratories. This protracted process frequently leads to diagnostic delays, increased transmission, and poorer patient outcomes. By enabling rapid, on-site testing, NPOC-NAATs are expected to accelerate diagnosis, facilitate earlier initiation of life-saving treatment, and ultimately curb the spread of the disease.
Complementing the molecular testing advancements, the updated guidance also endorses tongue swabs as an alternative specimen type for TB detection. This recommendation is particularly impactful for patients who struggle to produce sputum, such as young children, the elderly, or individuals who are very ill. Sputum collection can be challenging, invasive, and sometimes impossible for certain patient populations, creating significant diagnostic barriers. Tongue swabs offer a non-invasive, simpler, and more patient-friendly method of sample collection, broadening the accessibility of testing to a wider demographic and ensuring that no patient is left undiagnosed due to an inability to provide a traditional sample.
Furthermore, WHO recommends sputum pooling as an innovative strategy to enhance efficiency and reduce costs, particularly in environments with limited resources. This method allows laboratories to process multiple patient samples together, and if the pooled sample tests negative, all individual samples within that pool are considered negative. Only if a pooled sample tests positive are the individual samples then tested separately. This approach significantly increases laboratory throughput while conserving precious reagents and reducing the overall cost per test, making it a sustainable solution for scaling up TB diagnostic capacity in financially constrained health systems.
Dr. Tereza Kasaeva, director of WHO’s Department for HIV, TB, Hepatitis & STIs, underscored the significance of these developments, stating, "These new WHO recommendations mark a major step forward in making TB testing faster and more accessible. WHO urges countries and partners to work together to roll out these guidelines to close persistent diagnostic gaps and ensure that everyone with TB can be diagnosed early and start life-saving treatment without delay." Her statement highlights the urgent call to action for global partners to operationalize these guidelines and translate them into tangible improvements in TB care delivery.
The Persistent Global TB Challenge: Why New Strategies Are Crucial
Tuberculosis remains one of the world’s deadliest infectious diseases, despite being preventable and curable. According to WHO data, TB affects millions annually, with an estimated 10.6 million people falling ill with TB in 2022 and 1.3 million dying from the disease, making it the second leading infectious killer globally after COVID-19. The vast majority of these cases and deaths occur in low- and middle-income countries, where healthcare infrastructure is often fragile and resources are scarce.
The historical trajectory of TB diagnostics has evolved significantly. For decades, diagnosis relied heavily on sputum smear microscopy, a simple but insensitive method, and mycobacterial culture, which is highly sensitive but slow, often taking weeks for results. The introduction of rapid molecular tests, such as the GeneXpert system, marked a major leap forward, offering faster and more accurate detection of TB and drug resistance. However, these systems, while transformative, still often require centralized laboratory facilities, specialized personnel, and consistent electricity, posing significant logistical and financial hurdles for many countries.
The "persistent diagnostic gaps" mentioned by WHO are multifaceted. They include geographical barriers that prevent patients from reaching diagnostic centers, a shortage of trained laboratory personnel, inadequate equipment and infrastructure, and the high cost of existing testing platforms and reagents. These challenges lead to millions of people with TB going undiagnosed or experiencing significant delays in diagnosis, which perpetuates transmission cycles and increases the risk of developing drug-resistant forms of the disease. The new WHO recommendations are a direct response to these systemic failures, offering practical, scalable solutions designed to overcome these long-standing obstacles and align with WHO’s overarching "End TB Strategy," which aims to reduce TB incidence and mortality by 90% and 95% respectively by 2035.
Implementation and Operationalization: Guiding the Global Rollout
Successfully integrating these new recommendations into national TB programs worldwide will require concerted effort and strategic planning. WHO is not only issuing guidelines but also providing comprehensive supporting materials, including an operational handbook and an implementation toolkit. These resources are designed to guide laboratories and national TB programs through the entire adoption process, from initial training and workflow integration to quality assurance and supply chain management.
Key challenges in implementation will include securing adequate funding, training a vast workforce of healthcare professionals in decentralized settings, establishing robust quality control mechanisms for new testing platforms, and ensuring a steady supply chain for reagents and consumables. International partners, philanthropic organizations, and national governments will need to collaborate closely to overcome these hurdles, ensuring equitable access to these life-changing diagnostic tools. The goal is to build resilient TB diagnostic ecosystems that can sustain these advancements and contribute meaningfully to global TB elimination efforts.
The United States Context: A Targeted Approach Amidst Rising Cases
In stark contrast to WHO’s global push for expanded access and decentralization, the Centers for Disease Control and Prevention (CDC) continues to advocate for a targeted testing strategy for tuberculosis within the United States. This approach focuses on identifying and testing individuals at high risk for TB infection or disease, rather than implementing universal screening. The divergence in strategy is primarily dictated by the differing epidemiological landscapes: the US has a relatively low incidence of TB compared to many high-burden countries, coupled with a robust healthcare infrastructure.
However, the US has not been immune to challenges. The CDC noted in late 2025 that TB case counts and rates have been increasing since 2021. In 2024, the US recorded 10,388 TB cases, corresponding to an incidence rate of 3.1 per 100,000 population. This represented a 7.9% increase in case count and a 6.9% increase in rate compared to the previous year. This resurgence, while still placing the US among low-incidence countries, signals the need for continued vigilance and effective, targeted control measures. Potential factors contributing to this increase include post-pandemic disruptions to healthcare services, changes in immigration patterns from high-burden countries, and challenges in contact tracing and latent TB infection (LTBI) treatment completion.
The CDC recognizes two primary methods to detect TB infection, though neither distinguishes between latent infection and active disease:
- Tuberculin Skin Test (TST): This involves injecting a small amount of tuberculin purified protein derivative (PPD) into the skin. A positive reaction indicates TB infection but requires clinical interpretation based on risk factors.
- Interferon-Gamma Release Assays (IGRAs): These blood tests measure the immune response to TB proteins. Examples include QuantiFERON-TB Gold Plus and T-SPOT.TB. IGRAs are generally preferred for certain populations due to higher specificity.
If a patient tests positive for TB infection or presents with symptoms suggestive of active TB, such as a chronic cough (lasting more than two weeks), fever, night sweats, unexplained weight loss, or fatigue, the CDC recommends a comprehensive evaluation. This full diagnostic assessment includes:
- Medical History: Assessing risk factors for TB exposure, previous TB infection, or disease.
- Physical Examination: Evaluating general health and looking for signs of active disease.
- TB Infection Test (TST or IGRA): To confirm the presence of M. tuberculosis infection.
- Chest X-ray: To look for abnormalities characteristic of TB disease in the lungs.
- Bacteriologic Examination of Sputum or Other Specimens: This is crucial for confirming active pulmonary TB and for drug susceptibility testing. This often involves smear microscopy for acid-fast bacilli (AFB) and culture, followed by rapid molecular tests (e.g., NAATs) for definitive identification and drug resistance profiling.
Recent CDC guidance, developed in collaboration with the National Tuberculosis Controllers Association, has also refined screening practices for healthcare personnel (HCP). The updated recommendations reflect a shift from routine baseline screening for all HCP to a risk-based assessment. This means:
- Baseline TB Screening: Required for all HCP upon hire, including an individual risk assessment and TB infection testing.
- No Routine Annual Screening: Unless there is a known exposure or ongoing transmission in the healthcare setting, routine annual screening for HCP is no longer recommended.
- Post-Exposure Evaluation: Prompt evaluation and testing are crucial for HCP following any known exposure to TB.
- Symptom Monitoring: HCP should be educated to self-monitor for TB symptoms and report them promptly.
For 2026, the CDC emphasizes several important nuances for clinicians and laboratories interpreting TB test results. Blood-based interferon-gamma release assays (IGRAs) are strongly preferred for individuals who have received the BCG vaccine, as they are significantly less likely to produce false-positive results compared to tuberculin skin tests (TSTs) in this population. This distinction is critical for avoiding misdiagnosis and unnecessary treatment. Additionally, for individuals considered low risk for TB, a positive result from an initial test should ideally be confirmed with a second test – preferably using a different method – before initiating treatment. This confirmatory step helps to ensure diagnostic accuracy and prevent unnecessary therapy, thereby conserving resources and minimizing potential side effects for patients.
Diverging Paths, Shared Goal: Global vs. Domestic Realities
The contrasting strategies of WHO and CDC vividly illustrate how global health organizations and national public health bodies adapt their approaches based on specific epidemiological contexts, resource availability, and healthcare infrastructure. WHO’s recommendations prioritize expanded access, decentralization, and cost efficiency, particularly targeting high-burden, resource-limited settings where delayed diagnoses are rampant and healthcare access is often a luxury. Their focus on NPOC-NAATs, alternative sample types, and pooling strategies directly addresses these systemic barriers to ensure that diagnosis is not a privilege but a universal right.
Conversely, the CDC’s guidance reflects a more targeted, risk-based approach appropriate for a lower-incidence environment like the United States. While the US faces its own challenges with rising case numbers, its robust laboratory infrastructure, advanced molecular diagnostic capabilities, and comprehensive healthcare system allow for a more precise identification and management of TB cases. The emphasis here is on accurate diagnosis of active disease through multi-component evaluations and meticulous contact investigations, coupled with targeted screening of high-risk populations.
Despite these divergences in strategy, both organizations share the overarching goal of reducing the burden of tuberculosis and ultimately achieving its elimination. The global lessons learned from WHO’s push for decentralized diagnostics could potentially inform strategies for reaching underserved populations or managing outbreak scenarios within the US. Similarly, the CDC’s rigorous surveillance, diagnostic protocols, and drug resistance monitoring provide valuable models for global TB control programs striving for high standards of care.
Implications for Clinical Laboratories Worldwide
For clinical laboratories, the evolving landscape of TB diagnostics signals both significant opportunities and increasing complexity. Laboratories in high-burden settings, particularly those supported by national TB programs, will need to prepare for the adoption and integration of decentralized molecular platforms (NPOC-NAATs). This will involve investing in new equipment, validating alternative specimen types like tongue swabs, and optimizing high-throughput workflows such as pooling strategies. Comprehensive training programs for laboratory staff and healthcare workers in peripheral settings will be crucial to ensure accurate testing, quality control, and data management.
In the United States, clinical laboratories will continue to play a critical role in the accurate interpretation of TB infection tests (TSTs and IGRAs), the comprehensive diagnostic evaluations for active disease, and the adherence to updated guidelines for healthcare personnel screening. The ongoing rise in US TB cases underscores the persistent need for robust molecular diagnostics to confirm active disease, identify drug resistance, and facilitate rapid contact tracing. Laboratories will also need to stay abreast of the latest CDC guidance regarding confirmatory testing and the preferred use of IGRAs for BCG-vaccinated individuals to ensure diagnostic accuracy and avoid unnecessary treatment.
Across the globe, the broader trend of molecular diagnostics moving closer to the patient necessitates an adaptive and forward-thinking approach from clinical laboratories. This includes embracing technological advancements, validating new methodologies, and optimizing workflows to meet both the global demand for accessibility and the national imperative for targeted, high-quality care. The continuous evolution of TB diagnostic strategies underscores the dynamic nature of public health and the critical role that laboratories play in the ongoing fight against this ancient, yet persistent, disease.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
—Janette Wider
Leave a Reply